Germany's STADA Arz plans to accelerate expansion in Russian

30 March 2021

German drugmaker STADA Arzneimittel (SAZ: Xetra) plans to accelerate its expansion in the Russian pharmaceutical market in the coming years, Stefan Eder, executive vice president of STADA in Russia and the CIS, said in an interview with the Russian Kommersant business paper.

According to Mr Eder, over the past 15 years, STADA has invested over $1 billion in the Russian and CIS market, including a record $660 million on the purchase of Takeda's portfolio in 2020.

Mr Eder said in the next three years, the company plans to invest 13 million euros ($15.3 million) to increase the capacities of its local production sites of Nizhpharm and Hemofarm.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK